-K Podar Researcher Activity Profile

Research Author Detailed Information 

K Podar Publication Rate By Year

K Podar has published 2 paper(s) in 2006, 13 paper(s) in 2007, 5 paper(s) in 2008, for a total of 20 research publications in total.

K K Podar Author Information

LAST NAME: podar

FIRST NAME: K

INITIALS: k

AFFILIATION:

Papers

K Podar's Publication Record

1. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
2. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Year Published: 2006
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. klaus.podar@dfci.harvard.edu
3. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Year Published: 2006
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA. Ellen_weisberg@dfci.harvard.edu
4. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
5. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu
6. Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway. Year Published: 2007
Jerome Lipper Multiple-Myeloma Center, Department of Medical-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
7. Inhibition of the TGF-beta signaling pathway in tumor cells. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA.
8. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Year Published: 2007
The Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. yu-tzu_tai@dfci.harvard.edu
9. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Year Published: 2007
Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
10. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Year Published: 2007
Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
11. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Year Published: 2007
Dana-Farber Cancer Institute, Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu
12. The malignant clone and the bone-marrow environment. Year Published: 2007
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA.
13. MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Year Published: 2007
Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
14. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Year Published: 2008
15. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Year Published: 2008
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA 022115, USA. klaus_podar@dfci.harvard.edu
16. Inhibition of the TGF-beta signaling pathway in tumor cells. Year Published: 2007
Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA.
17. The malignant clone and the bone-marrow environment. Year Published: 2007
Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA. klaus_podar@dfci.harvard.edu
18. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Year Published: 2008
19. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Year Published: 2008
The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Center for Myeloma Research, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. dharminder_chauhan@dfci.harvard.edu
20. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Year Published: 2008
Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.